The Annals
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


Drug Intelligence & Clinical Pharmacy: Vol. 19, No. 1, pp. 62-66.
© 1985 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brushwood, D.
Right arrow Articles by Abood, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brushwood, D.
Right arrow Articles by Abood, R.


Research Articles

A third class of drugs: an overview

DB Brushwood and RR Abood

Drug distribution in the U.S. allows certain products to be used only under the supervision of a physician or dentist. The distribution of other products is underrestricted, such that they may be used by consumers without any supervision. This article discusses the possibility of establishing a third class of drugs that would be available without a prescription but could be purchased only from a pharmacist. The current prescription-to-OTC switch process may provide an excellent opportunity to establish a third class of drugs. However, significant obstacles exist to such a move. For there to be sufficient public policy justification for a third class of drugs, it must be shown that the public will benefit through increased quality of health care and that the economic consequences will not be prohibitive.





homecopy help contact us subscription past issues search current issue
Copyright © 1985 by Harvey Whitney Books Company.